Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced three clinical
studies4-6 focused on its Barrigel™ rectal spacer are to be
presented at the 2024 American Society for Radiation Oncology
(ASTRO) Annual Meeting, which will take place in Washington, DC,
from September 29 to October 2, 2024. The featured data will
contribute to the expanding body of clinical evidence regarding the
safety and efficacy of Barrigel™ rectal spacer, the first and only
commercial hyaluronic acid rectal spacer that separates the
prostate from the rectum to protect the rectum during prostate
cancer radiation therapy.1 The company will also be exhibiting and
hosting a Barrigel™ Educational Symposium at the John F. Kennedy
Center for the Performing Arts.
Barrigel™ rectal spacer is a Non-Animal Stabilized Hyaluronic
Acid (NASHA) spacer designed to reduce radiation that reaches the
rectum during prostate cancer radiation therapy, with the goal of
improving patient quality of life. It has been clinically proven to
significantly reduce unwanted radiation exposure in 98.5% of
patients.1 Barrigel™ rectal spacer is indicated for prostate cancer
patients with T1-T3b disease.
“Radiation therapy can have a significant and positive effect on
the treatment of prostate cancer, and these data further
demonstrate Barrigel™ rectal spacer as a safe and effective option
for patients that reduces prostate radiation side effects,” said
Jacqueline Welch, Vice President of Global Clinical and Scientific
Operations at Teleflex. “This research underscores Teleflex’s
commitment to advancing therapies that improve patient outcomes and
set new benchmarks in prostate cancer care.”
Presentation Information:
1. Impact of Hyaluronic
Acid (HA) Rectal Spacer Quality Score (SQS) and Fischer-Valuck (FV)
Spacer Symmetry Score on Rectal Dosimetry and Acute and Late
Gastrointestinal (GI) Toxicity Outcomes – an Australian Experience
(Abstract #3222); Tuesday, Oct. 1, 2:30-3:45 ET, Hall
CThis retrospective multi-institutional review assessed
the implant quality and gastrointestinal (GI) toxicity of Barrigel™
rectal spacer in prostate cancer patients treated with moderately
hypofractionated external beam radiotherapy (EBRT).4
2. Rectal Wall
Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal
Protocol (Abstract #3185); Tuesday, Oct. 1, 2:30-3:45 ET, Hall
CThis retrospective analysis assessed the outcomes of
inadvertent rectal wall infiltration (RWI), which can occur with
rectal spacers, following use of Barrigel™ rectal spacer.5
3. Hyaluronic Acid
Rectal Spacer in Locally Recurrent Prostate Cancer with Prior
Radiation Receiving SBRT: on Feasibility, Safety, and Toxicity
(Abstract #3236); Tuesday, Oct. 1, 2:30-3:45 ET, Hall
CThis study evaluated outcomes in prostate cancer patients
who had previously been treated with EBRT but experienced localized
recurrence and were treated with SBRT. These patients often are not
candidates for repeat radiation due to concerns about safely
implanting a rectal spacer in previously irradiated tissue.6
Barrigel™ Educational Symposium Information:
On September 30 at 6:00 p.m. at the REACH at the John F. Kennedy
Center for Performing Arts, Teleflex will host an educational
symposium, “The Science of Personalized Spacing.” The event will
feature a panel discussion with Peter F. Orio III, DO, MS, FASTRO,
FABS*; Daniel Kim, MD*; Nedhim Ruhotina, MD*; Michael Greenberg,
MD*; and Martin King, MD,* who will discuss best practices for
addressing challenging cases with Barrigel™ rectal spacer.
Teleflex Booth Activities:
At the Teleflex booth 1223 in the ASTRO Annual Meeting Exhibit
Hall, clinicians can view the Barrigel™ rectal spacing procedure or
perform it via a simulation. In addition, Michael Greenberg, MD*
and John Han-Chih Chang, MD* will conduct clinical discussions and
case presentations on September 29 and 30. Dr. Greenberg will
present at 11:00 a.m. and 3:00 p.m. and Dr. Chang will speak at
1:00 p.m. and 4:00 p.m.
About Barrigel™ Rectal
SpacerBarrigel™ rectal spacer is the first and only
hyaluronic acid rectal spacer that separates the prostate from the
rectum to protect the rectum during radiation therapy treatment for
prostate cancer.1 Barrigel is made from Non-Animal Stabilized
Hyaluronic Acid (NASHA).7
Hyaluronic acid is a substance naturally present in the human
body and is highly compatible and fully absorbable. NASHA has a
proven history of safety and efficacy in a wide variety of medical
applications in men, women and children worldwide.8,9
Barrigel™ rectal spacer has been proven to significantly reduce
unwanted side effects from prostate cancer radiation therapy and is
approved for rectal spacing in the United States, Australia, and
Europe. Barrigel™ rectal spacer is indicated for prostate cancer
patients with T1-T3b disease. For more information about
Barrigel™ rectal spacer, please visit
https://barrigel.com/hcp/barrigel-control-matters.
Barrigel™ Rectal Spacer Important Safety
InformationBarrigel™ rectal spacer is intended to
temporarily position the anterior rectal wall away from the
prostate during radiotherapy for prostate cancer and, in creating
this space, it is the intent of Barrigel™ rectal spacer to reduce
the radiation dose delivered to the anterior rectum. Barrigel™
rectal spacer is composed of biodegradable material and maintains
space for the entire course of prostate radiotherapy treatment and
is intended to be absorbed by the patient’s body over time.
Barrigel™ rectal spacer should only be administered by qualified
and properly trained physicians with experience in ultrasound
guidance and injection techniques in the urogenital/pelvic
area.
As with any medical treatment, there are some risks involved
with the use of Barrigel™ rectal spacer. Potential complications
associated with the use of Barrigel include, but are not limited
to: pain associated with Barrigel™ rectal spacer injection; needle
penetration of the bladder, prostate, rectal wall, rectum, or
urethra; injection of Barrigel™ rectal spacer into the bladder,
prostate, rectal wall, rectum, urethra, or intravascularly; local
inflammatory reactions; infection; urinary retention; rectal
mucosal damage, ulcers, necrosis; bleeding; constipation; and
rectal urgency. More information on indications, contraindications,
warnings and instructions for use can be found in the Instructions
For Use at www.barrigel.com.
Caution: Federal (USA) law restricts this device to sale by or
on the order of a physician.
*Peter F. Orio III, Daniel Kim, Nedhim Ruhotina, Michael
Greenberg, Martin King and John Han-Chih Chang are paid consultants
of Teleflex.
About Teleflex IncorporatedAs a global provider
of medical technologies, Teleflex is driven by our purpose to
improve the health and quality of people’s lives. Through our
vision to become the most trusted partner in healthcare, we offer a
diverse portfolio with solutions in the therapy areas of
anesthesia, emergency medicine, interventional cardiology and
radiology, surgical, vascular access, and urology. We believe that
the potential of great people, purpose driven innovation, and
world-class products can shape the future direction of
healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™,
Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands
united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For
more information, please visit teleflex.com.
References:
- Mariados NF, Orio PF, Schiffman Z, et al. Hyaluronic acid
spacer for hypofractionated prostate radiation therapy: a
randomized clinical trial. JAMA Oncol. 2023;
e1-e8.**
- King MT, Svatos M, Orio PF III et al. Evaluating the
Quality-of-Life Effect of Apical Spacing with
Hyaluronic Acid Prior to Hypofractionated Prostate Radiation
Therapy: A Secondary Analysis, Pract Radiat Oncol. 2023;e1-e6.
(Study sponsored by Palette Life Sciences, now part of
Teleflex).**
- Data on File. As of 06/01/2024.
- Lin YH, et al. Impact of Hyaluronic Acid (HA) Rectal Spacer
Quality Score (SQS) and Fischer-Valuck (FV) Spacer Symmetry Score
on Rectal Dosimetry and Acute and Late Gastrointestinal (GI)
Toxicity Outcomes – an Australian Experience. Abstract #3222.
Presented at ASTRO 2024.
- Hong A, Bolton D, Ramani S, et al. Rectal wall infiltration
with hyaluronic acid based rectal spacer reversal protocol.
Abstract #3185. Presented at ASTRO 2024.
- McLean L, et al. Hyaluronic Acid Rectal Spacer in Locally
Recurrent Prostate Cancer with Prior Radiation Receiving SBRT: on
Feasibility, Safety, and Toxicity. Abstract #3236. Presented at
ASTRO 2024.
- Barrigel Injectable Gel Instructions for Use (2022).
- Restylane® celebrates 25 years of natural-looking results with
its signature line of hyaluronic acid fillers. 2021. Available at:
https://www.prnewswire.com/news-releases/restylane-celebrates-25-years-of-natural-looking-results-with-its-signature-line-of-hyaluronic-acid-fillers-301388779.html.
Accessed Sept 30, 2021.
- Svatos M, Chell E, Low DA, et al. Symmetry, separation, and
stability: Physical properties for effective dosimetric space with
a stabilized hyaluronic acid spacer. Med Phys. 2024; 1-15.
https://doi.org/10.1002/mp.17292**
**Study sponsored by Palette Life Sciences, now part of
Teleflex.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA,
Pilling, QuikClot, Rüsch, Titan SGS, UroLift and Weck are
trademarks or registered trademarks of Teleflex Incorporated or its
affiliates, in the U.S. and/or other countries. All other
trademarks are the property of their respective owners. © 2024
Teleflex Incorporated. All rights reserved. APM942A
Contacts:TeleflexLawrence KeuschVice President,
Investor Relations and Strategy
Developmentinvestor.relations@teleflex.com610-948-2836
Media Contact:Glenn SilverPartner National Media Relations
Specialistglenn.silver@finnpartners.com646-871-8485
Teleflex (NYSE:TFX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Dec 2023 to Dec 2024